Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX07 + HLX10 + chemotherapy and HLX07 monotherapy in advanced metastatic gastric cancer
CTR20220330Phase 2Terminated
- Sponsor
- HyBioPharma
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pimurutamab and serplulimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by HyBioPharma. Primary endpoints: Objective response rate and Progression-free survival. Started Mar 2022; status: terminated.
02
Drugs
pimurutamabserplulimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20220330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220330.